According to Zhitong Finance APP, AMASSE CAPITAL (08168) saw its shares drop nearly 30% at the end of trading, with a total daily fluctuation of 69%. The stock surged 118% yesterday on high volume and rose over 34% this morning. As of the time of writing, it is down 17.42%, priced at 0.128 Hong Kong dollars, with a transaction value of 10.4804 million Hong Kong dollars.

In news, AMASSE CAPITAL recently announced a placement of up to approximately 0.1047 billion shares, representing about 8.69% of the enlarged share capital, with a placement price of 0.057 Hong Kong dollars per share, a discount of approximately 19.72% compared to the closing price of 0.071 Hong Kong dollars on Monday. The total proceeds are expected to be around 5.97 million Hong Kong dollars. Additionally, the company has signed a memorandum of understanding with Tingchuang (Tancheng) Biotechnology, in which the parties agree to engage in sincere discussions to establish a formal partnership agreement. It is reported that Tingchuang (Tancheng) Biotechnology is primarily engaged in the research, development, production, and sale of probiotic products in China.

Furthermore, AMASSE CAPITAL will announce its annual results for the year ending September 30, 2024, on December 30. The company issued a profit warning earlier this month, indicating, based on preliminary assessments of its unaudited consolidated management accounts for the year ending September 30, 2024 (the fiscal year 2024), that it expects a consolidated net loss of approximately 8.9 million Hong Kong dollars, compared to a consolidated net loss of approximately 1.9 million Hong Kong dollars for the year ending September 30, 2023.